Torsemide versus furosemide in heart failure patients: Insights from duke university hospital

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 5, 2015, Pages 438-443

  Mentz, Robert J ^a   Buggey, Jonathan ^a   Fiuzat, Mona ^a   ErsbØll, Mads K ^b   Schulte, Phillip J ^a   DeVore, Adam D ^a   Eisenstein, Eric L ^a   Anstrom, Kevin J ^a   O'Connor, Christopher M ^a   Velazquez, Eric J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Rigshospitalet   (Denmark)

Author keywords

furosemide; heart failure; loop diuretics; torsemide

Indexed keywords

FUROSEMIDE; TORASEMIDE; LOOP DIURETIC AGENT; SULFONAMIDE;

ADULT; AGED; ARTICLE; COMORBIDITY; DATA BASE; FEMALE; HEART FAILURE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL; UNIVERSITY HOSPITAL; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; ECHOGRAPHY; FACTUAL DATABASE; MIDDLE AGED; NORTH CAROLINA; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TERTIARY CARE CENTER; TREATMENT OUTCOME;

ACADEMIC MEDICAL CENTERS; AGED; COMORBIDITY; DATABASES, FACTUAL; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NORTH CAROLINA; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SULFONAMIDES; TERTIARY CARE CENTERS; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 84930208303     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000212     Document Type: Article

References (23)

1. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med. 1994;154:1905-1914
2. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216
3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American heart association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62:e147-e239
4. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59:2145-2153
5. Bikdeli B, Strait KM, Dharmarajan K, et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol. 2013;61:1549-1550
6. Clasen W, Khartabil T, Imm S, et al. Torasemide for diuretic treatment of advanced chronic renal failure. Arzneimittelforschung. 1988;38:209-211
7. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharm. 1991;205:145-150
8. Goodfriend TL, Ball DL, Oelkers W, et al. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:PL45-PL50
9. Harada K, Izawa H, Nishizawa T, et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009;53:468-473
10. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-2035
11. Kasama S, Toyama T, Hatori T, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92:1434-1440
12. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-520
13. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507-513
14. Muller K, Gamba G, Jaquet F, et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. Eur J Heart Fail. 2003;5:793-801
15. Dinicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure?. Future Cardiol. 2012;8:707-728
16. Mentz RJ, Broderick S, Shaw LK, et al. Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. Eur J Heart Fail. 2014;16:854-860
17. Boyle CA, Decoufle P. National sources of vital status information: extent of coverage and possible selectivity in reporting. Am J Epidemiol. 1990;131:160-168
18. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083-3107
19. Lopez B, Querejeta R, Gonzalez A, et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension. 2009;53:236-242
20. Lopez B, Gonzalez A, Beaumont J, et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:859-867
21. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63: 1123-1133
22. Butler J, Fonarow GC, Gheorghiade M. Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA. 2013;310:2035-2036
23. Stroupe KT. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17: 429-440